1. Home
  2. PCRX vs INN Comparison

PCRX vs INN Comparison

Compare PCRX & INN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • INN
  • Stock Information
  • Founded
  • PCRX 2006
  • INN 2010
  • Country
  • PCRX United States
  • INN United States
  • Employees
  • PCRX N/A
  • INN N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • INN Real Estate Investment Trusts
  • Sector
  • PCRX Health Care
  • INN Real Estate
  • Exchange
  • PCRX Nasdaq
  • INN Nasdaq
  • Market Cap
  • PCRX 604.7M
  • INN 708.0M
  • IPO Year
  • PCRX 2011
  • INN 2011
  • Fundamental
  • Price
  • PCRX $22.84
  • INN $6.75
  • Analyst Decision
  • PCRX Buy
  • INN
  • Analyst Count
  • PCRX 10
  • INN 0
  • Target Price
  • PCRX $27.60
  • INN N/A
  • AVG Volume (30 Days)
  • PCRX 787.3K
  • INN 747.7K
  • Earning Date
  • PCRX 02-27-2025
  • INN 02-24-2025
  • Dividend Yield
  • PCRX N/A
  • INN 4.75%
  • EPS Growth
  • PCRX N/A
  • INN N/A
  • EPS
  • PCRX N/A
  • INN 0.07
  • Revenue
  • PCRX $694,957,000.00
  • INN $736,287,000.00
  • Revenue This Year
  • PCRX $4.83
  • INN $0.15
  • Revenue Next Year
  • PCRX $2.16
  • INN $1.08
  • P/E Ratio
  • PCRX N/A
  • INN $92.17
  • Revenue Growth
  • PCRX 4.40
  • INN 0.72
  • 52 Week Low
  • PCRX $11.16
  • INN $5.66
  • 52 Week High
  • PCRX $34.01
  • INN $7.22
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 72.97
  • INN 52.31
  • Support Level
  • PCRX $18.18
  • INN $6.67
  • Resistance Level
  • PCRX $22.36
  • INN $6.89
  • Average True Range (ATR)
  • PCRX 1.17
  • INN 0.14
  • MACD
  • PCRX 0.33
  • INN -0.01
  • Stochastic Oscillator
  • PCRX 99.15
  • INN 69.17

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

About INN Summit Hotel Properties Inc.

Summit Hotel Properties Inc is a U.S.-based hotel investment company focusing on select-service hotels in the upscale and upper-midscale properties in the U.S. Substantially all of Summit's assets are held and operated by its Operating Partnership, Summit Hotel OP, LP, in which the company holds general and limited partnership interests. The firm has one segment in activities related to investing in real estate. Summit's revenue streams include Room and Other hotel operations revenue. Room comprises the majority of total revenues. The firm's hotels are located in various markets, such as corporate offices, retail centers, airports, state capitols, convention centers, and leisure attractions. Summit's hotels operate under brands, including Marriott, Hilton, Hyatt, and Holiday Inn.

Share on Social Networks: